Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Company profile
Ticker
NVS, NVSEF
Exchange
Website
CEO
Vasant Narasimhan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NVS stock data
Latest filings (excl ownership)
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 24
SC TO-C
Information about tender offer
6 Feb 24
SC TO-C
Information about tender offer
5 Feb 24
6-K
Current report (foreign)
31 Jan 24
6-K
Current report (foreign)
31 Jan 24
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
31 Jan 24
20-F
2023 FY
Annual report (foreign)
31 Jan 24
6-K
Current report (foreign)
8 Jan 24
6-K
Current report (foreign)
11 Dec 23
6-K
Current report (foreign)
5 Dec 23
Transcripts
NVS
Earnings call transcript
2022 Q2
19 Jul 22
NVS
Earnings call transcript
2022 Q1
26 Apr 22
NVS
Earnings call transcript
2021 Q4
2 Feb 22
NVS
Earnings call transcript
2021 Q3
26 Oct 21
NVS
Earnings call transcript
2021 Q2
21 Jul 21
NVS
Earnings call transcript
2020 Q3
27 Oct 20
NVS
Earnings call transcript
2020 Q3
27 Oct 20
Latest ownership filings
SC 13G/A
BlackRock Inc.
2 Feb 24
144
Notice of proposed sale of securities
19 Sep 23
SC 13G/A
BlackRock Inc.
1 Feb 23
3
PHARMA AG NOVARTIS
27 Jun 22
SC 13G
BlackRock Inc.
4 Feb 22
SC 13G/A
XOMA Corp
19 Aug 20
3
Cellular Biomedicine Group, Inc.
14 Aug 20
4
PHARMA AG NOVARTIS
16 Jul 20
3
PHARMA AG NOVARTIS
13 Jul 20
4
Akouos, Inc.
2 Jul 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
5.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1035 |
Opened positions | 112 |
Closed positions | 245 |
Increased positions | 322 |
Reduced positions | 356 |
13F shares | Current |
---|---|
Total value | 10.42 tn |
Total shares | 115.23 mm |
Total puts | 90.20 k |
Total calls | 181.00 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Dodge & Cox | 13.17 mm | $1.33 tn |
Primecap Management | 12.91 mm | $1.30 tn |
MS Morgan Stanley | 7.09 mm | $716.10 bn |
Dimensional Fund Advisors | 6.08 mm | $613.70 bn |
Loomis Sayles & Co L P | 6.01 mm | $606.82 mm |
BEN Franklin Resources | 5.91 mm | $597.24 bn |
Wellington Management | 4.75 mm | $479.26 bn |
GS Goldman Sachs | 3.54 mm | $357.02 bn |
Renaissance Technologies | 2.84 mm | $286.56 mm |
PFG Principal Financial Group Inc - Registered Shares | 2.51 mm | $253.30 bn |
News
Novartis Pharmaceuticals Canada Announced Health Canada Grants Approval Of The Eye-tracking Neurological Assessment For Multiple Sclerosis For Use In Tracking Disease Progression In People Living With MS
25 Mar 24
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund
25 Mar 24
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
22 Mar 24
On 21 March 2024, The CHMP Adopted A Positive Opinion, Recommending The Granting Of A Marketing Authorization For Novartis' Fabhalta1, Intended For The Treatment Of Paroxysmal Nocturnal Haemoglobinuria
22 Mar 24
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
20 Mar 24